Business context and reporting period
Emerald Medical Applications Corp. (the registrant named in the filing) filed this unaudited Form 10-Q for the quarter and nine months ended September 30, 2017. The request metadata names Quantum X Labs Inc.; that does not match the filing, and the identity should be verified. Emerald develops DermaCompare, imaging and analytics software intended to help clinicians monitor skin lesions. It reported no revenue and had no employees on payroll as of the reporting date. Beginning in July 2017, it outsourced development and maintenance to conserve cash.
Financial results and liquidity
- Revenue: $0 for both the three and nine months ended September 30, 2017, and the comparable 2016 periods.
- Quarterly results: Operating expenses and operating loss were $144,608. Net loss was $57,654, versus $1,100,480 in the 2016 quarter as shown in the statements of operations. Basic and diluted loss per share was reported as $0.00, versus $0.06.
- Nine-month results: Operating expenses and operating loss were $1,177,035. Net loss was $1,415,989, versus $4,188,684 in the 2016 statements of operations. Loss per share was $0.07, versus $0.22. Research and development expense was $359,600 and general and administrative expense was $817,435.
- Cash flow: Net cash used in operating activities was $615,719; investing activities provided $8,430; financing activities provided $606,232. Cash decreased by $1,057 to $3,429.
- Balance sheet: Current assets were $34,659, including $3,429 cash and $31,230 other receivables; current liabilities were $887,509, producing negative working capital of $852,850. Total liabilities were $1,493,674, including $923,154 in convertible notes, current and long-term. Total assets were $58,894 and stockholders’ deficit was $1,434,780.
- Margins: No revenue was reported, so a revenue margin is not meaningful.
Changes, outlook, and material matters
- Quarterly operating expenses declined from $733,275 in 2016, primarily reflecting lower R&D and general and administrative costs. Nine-month operating expenses declined from $3,797,361; management attributed much of the decrease to merger-related and share-based compensation expenses in 2016.
- Management said R&D activity was curtailed in the third quarter because funds were depleted. It estimated the company might need up to an additional $1.5 million over the next 12 months to implement its plan and fund operations. No assurance was given that financing would be obtained.
- The filing states that substantial doubt exists about the company’s ability to continue as a going concern. Management was seeking equity financing and was in late-stage discussions with potential private investors.
- In August 2017, the company settled a dispute with noteholders: certain notes were extended to June 2019 with increased principal, and preferred shares convertible into common stock were issued. The settlement generated reported charges of $440,684 to general and administrative expense and $219,276 to finance expense. The filing also says $195,000 of other notes came due during the nine-month period; discussions to extend them were ongoing.
- Subsequent to quarter-end, former employees pursued a liquidation request over unpaid liabilities. A December 20 court order required payment of pension debts within 21 days and other debts within 60 days or a winding-up order could follow. The filing describes the claimed amounts as below $96,000 and included in current liabilities. A separate former CEO lawsuit seeks $100,000; the company disputes the claim, and counsel could not estimate the outcome.
- A December 2017 proposed transaction involving note and warrant holders had not closed as of the filing date. The board was also considering establishing another Israeli subsidiary. These were proposals, not completed outcomes.
- The company restated 2016 information for an omitted derivative liability. Disclosure controls and procedures were deemed ineffective as of September 30, 2017.
Most important facts to verify
- Confirm the registrant’s identity: the filing is for Emerald Medical Applications Corp., not Quantum X Labs Inc.
- Reconcile inconsistent reported loss figures: the statements of operations show nine-month net loss of $1,415,989, while the cash flow statement shows $1,752,261 and MD&A contains additional conflicting loss figures. The filing text does not provide a clear reconciliation.
- Reconcile finance income/expense disclosures: the statements report third-quarter finance income of $86,954, while MD&A cites a different prior-period amount and describes the current-period item differently.
- Confirm balance-sheet and liquidity figures against the underlying statements: MD&A describes $58,894 as current assets, although the balance sheet reports that amount as total assets and current assets of $34,659. MD&A also cites a different prior-year total-liability figure.
- Verify cash runway, financing status, and whether the proposed noteholder transaction closed; the filing reports only $3,429 in cash at September 30, 2017 and identifies substantial going-concern uncertainty.
- Track the former-employee liquidation proceeding, payment deadlines, and the former CEO lawsuit, along with any unpaid or renegotiated debt obligations.